With Disarm deal, Atlas returns to Lilly to take neuro program forward 

Eli Lilly’s acquisition of Disarm marks the second time an Atlas-incubated newco has turned to the pharma to advance its neurology assets. 

Under the deal, Eli Lilly and Co. (NYSE:LLY) will acquire Disarm Therapeutics Inc. for $135 million up front and $1.2 billion in milestones...